- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
CSE Expands International Reach with Israeli Cannabis Firm’s Debut
Israel-based marijuana firm IM Cannabis made its public debut on Monday after its shares started trading on the CSE.
Investors gained access to a new international play on the Canadian Securities Exchange (CSE) as Israel-based medical marijuana producer and researcher IM Cannabis (IMC) (CSE:IMCC) officially launched on the exchange.
IMC started trading on Tuesday (November 5) under the ticker symbol “IMCC.” Shares of IMC opened at C$0.75 that day; as of 11:54 a.m. EST, the company was up 0.67 percent.
The company raised approximately C$20.4 million through a private placement in connection with its public launch. According to CEO Oren Shuster, IMC does not need to raise any more capital.
He added that despite the current landscape for marijuana investments on Canadian exchanges, he thinks his company is arriving at a proper time given its long-term roadmap.
“If you talk about timing, if you’re looking for the short term — and if we were only a financial player — it’s the worst time to go public,” Shuster told the Investing News Network (INN). “Because we don’t have to raise more money, and we are not looking at the short term, I think that for us it doesn’t matter what is happening in the short term.”
Despite being based in Israel, IMC is pursuing a European play for its marijuana operations — including its current shipment of medical cannabis to Germany through its pharmaceutical distribution company Adjupharm, which IMC acquired in March.
The company is betting on the development of the European market as a powerhouse in the medical cannabis space, a concept that has been shared by fellow players with interests in the continent, despite snags such as exporting problems.
Shuster touted the different options his company offers to investors looking within the marijuana space, with its presence in Israel and Europe, compared to the Canadian market. Shuster commented that he doesn’t see his company adding operations in Canada anytime soon.
He said investors are tired of promises from cannabis companies and are looking for existing results.
“The sentiment is now very negative now in the market because people understand that the market in Canada, it’s starting to be very competitive and there’s a strong push in the prices, and the projections that many companies gave are not close to reality,” he told INN.
The executive added that the company plans to expand its assets in Europe to include operations in Portugal and Greece.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.